Personalized medicine articles within Nature

Featured

  • Books & Arts |

    David Dobbs extols a history of New York's Bellevue hospital, a crucible of discovery in medicine.

    • David Dobbs

  • Outlook |

    Advanced tumours may have met their match with new drugs, but why have these treatments proved ineffective at stopping early-stage tumours from coming back?

    • Carolyn Brown

  • Outlook |

    We need to combine epidemiology and exposures research to fulfil the potential of precision medicine, say John Leppert and Chirag Patel.

    • John Leppert
    •  & Chirag Patel

  • Outlook |

    The first medical interventions were often individualized but ineffective, because doctors lacked an understanding of disease biology. As medicine became more scientific, physicians started grouping patients by disease. Now, genetic insights let doctors consider their patients' unique make-up when prescribing treatments.

    • Amber Dance

  • Outlook |

    Living with a rare disease but no concrete diagnosis can be difficult. Genetic sequencing may finally provide a solution.

    • Emily Sohn

  • Outlook |

    Remarkable progress in sequencing technologies and data handling is making personalized genome analysis an increasingly common feature of health care.

    • Andrew R. Scott

  • Outlook |

    It may not be possible to protect the identity of genomic data. But how much of a problem is that?

    • Neil Savage

  • Outlook |

    The US Precision Medicine Initiative (PMI) aims to gather health data on at least one million volunteers. Kathy Hudson, deputy director for science, outreach and policy at the US National Institutes of Health (NIH), led its creation, and spoke to Nature about the challenges she faced.

    • Eric Bender

  • Outlook |

    When data-gathering precision-medicine projects build trust with their users, patients and researchers both benefit.

    • Katherine Bourzac

  • Outlook |

    After a series of setbacks, genetic therapies are finally moving beyond small academic trials towards approval as treatments.

    • Eric Bender

  • Technology Feature |

    Ways to directly convert one mature cell type into another may eventually offer a safer, faster strategy for regenerative medicine.

    • Michael Eisenstein

  • Outlook |

    Strategies to destroy treatment-defying tumours in men with prostate cancer are beginning to make a difference.

    • Neil Savage

  • Outlook |

    Work to determine which prostate cancers are truly dangerous may finally be coming to fruition.

    • Sarah Deweerdt

  • Outlook |

    The standard blood test for prostate cancer led to a spike in diagnoses of the disease. But the technique's results are often misleading — and conflicting studies have not helped to forge a consensus.

    • Emily Sohn

  • Outlook |

    Tim Lu's synthetic-biology research at Massachusetts Institute of Technology in Cambridge combines biological engineering with electronics and computer science to create bacteria that make structural proteins containing tiny semi-conductors called quantum dots. He explains how genome-editing techniques are furthering his research and their role in treating disease.

    • Will Tauxe

  • Outlook |

    Technology is allowing researchers to generate vast amounts of information about tumours. The next step is to use this genomic data to transform patient care.

    • Jill U. Adams

  • Outlook |

    Research is attacking colorectal cancer on many fronts, with varying degrees of success. But solving these five central puzzles is likely to be crucial.

    • Shraddha Chakradhar

  • Outlook |

    Oncologist Victor Velculescu, co-director of cancer biology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, describes how circulating tumour DNA can be used to improve the detection and treatment of colorectal cancer.

    • Eric Bender

  • Outlook |

    In 2009, Hans Clevers and Toshiro Sato (then a postdoc in Clevers' lab) demonstrated a powerful new model to study development and disease: a three-dimensional 'organoid' derived from adult stem cells that replicates the structure of cells lining the intestine. More than 100 labs worldwide are now working with different types of organoid to study cancer and other diseases. Clevers, at the Hubrecht Institute in Utrecht, the Netherlands, discusses the potential of this approach.

    • Eric Bender

  • Letter |

    The authors show that a large fraction of tumour mutations is immunogenic and predominantly recognized by CD4+ T cells; they use these data to design synthetic messenger-RNA-based vaccines specific against tumour mutations, and show that these can reject tumours in mice.

    • Sebastian Kreiter
    • , Mathias Vormehr
    •  & Ugur Sahin

  • Outlook |

    Tailoring cancer treatment to individual and evolving tumours is the way of the future, but scientists are still hashing out the details.

    • Lauren Gravitz

  • News |

    Profiles of a researcher's genes, proteins and more show personalized genomic medicine in action.

    • Carina Dennis

  • Outlook |

    Systems science can provide guidance in capturing the complementary approaches to healthcare, says Jan van der Greef.

    • Jan van der Greef

  • News Q&A |

    Telomeres may not predict how long we'll live, but they can still revolutionise medicine, says Nobel laureate Elizabeth Blackburn.

    • Jo Marchant

  • Editorial |

    Targeted therapies work, but need help to fulfil their potential.

Browse broader subjects

Browse Personalized medicine across other nature.com journals